The aim of this study was to determine whether left ventricular ejection fraction (LVEF) influences the relationship between abnormal myocardial sympathetic innervation imaging by iodine 123 meta-iodobenzylguanidine ( 123 I-mIBG) and outcomes in patients with heart failure (HF). 
P atients with heart failure (HF) are at an increased risk of death secondary to both arrhythmia and HF progression regardless of left ventricular ejection fraction (LVEF) (1, 2) . When Ͻ45%, LVEF is a powerful predictor of adverse events in patients with HF (3) . However, few measures are available to risk-stratify HF patients with a normal or mildly reduced LVEF. In particular, although subjects with HF and an LVEF Ͼ35% are at an increased risk of sudden death compared with persons without HF, there is currently no widely applicable method to risk-stratify these patients and identify those who may benefit from advanced therapies such as implantable cardioverter-defibrillators (4) .
Evaluations of LVEF are often imprecise, related to interobserver variability, differences due to imaging modality, and physiological variation over time related to changes in loading conditions and heart rate (5) . The use of experienced core laboratories appears to improve the uniformity of LVEF assessment by echocardiography in multicenter clinical trials, and profession guidelines for their use are now available (6) . When LVEF cutoffs are used in multicenter clinic trials, discordance in LVEF results between the enrolling site and a core laboratory is not uncommon (7) . Iodine 123 meta-iodobenzylguanidine ( 123 I-mIBG) is a radiopharmaceutical that is selectively taken up into pre-synaptic sympathetic nerve endings via the norepinephrine reuptake system but is not metabolized (8, 9) . Reductions in 123 I-mIBG uptake therefore may represent abnormalities of pre-synaptic norepinephrine reuptake or sustained hyperactivity of the sympathetic nervous system in HF with pre-synaptic norepinephrine depletion. Abnormal cardiac sympathetic innervation imaging using 123 I-mIBG is associated with a higher risk of mortality and morbidity among patients with HF and an LVEF Յ35% (10) . Data regarding the prognostic utility of 123 I-mIBG in HF with an LVEF Ͼ35% are limited (11) .
We hypothesized that the association of lower heart-to-mediastinum ratio (H/M ratio) with mortality and potentially lethal arrhythmic events will be equivalent among HF patients across the spectrum of left ventricular (LV) systolic function. To gain greater insight into the utility of 123 I-mIBG imaging in HF with EF Ͼ35%, we performed a retrospective analysis of the ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) trial database using LVEF determined by a core laboratory in which a subset of patients had an LVEF Ͼ35%. Specifically, we sought to assess for the presence of effect modification of LVEF on the relationship between H/M ratio and the risk of death or potentially lethal arrhythmic event and of cardiovascular death, arrhythmic event, or HF progression.
M E T H O D S
Patient population. The ADMIRE-HF trial was the combination of 2 identical open-label, multicenter trials designed to provide prospective validation of the prognostic role of cardiac sympathetic innervation imaging using 123 I-mIBG in patients with HF (12) . The study enrolled 985 HF subjects who met the following inclusion criteria: New York Heart Association (NYHA) functional class II or III symptoms, an ischemic or nonischemic cardiomyopathy with a site-reported LVEF Յ35%, and receiving evidence-based medical therapy including a beta-blocker and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. All enrolled patients underwent planar imaging of the anterior thorax at 15 min and 4 h after 123 I-mIBG injection. Subjects were followed for a median of 17 months to the primary composite endpoint of cardiac death, potentially life-threatening arrhythmic event, or HF progression. The extent of 123 ImIBG uptake was quantified at a core reading facility, and clinical events were adjudicated by an endpoint adjudication committee as previously described (13) . A potentially life-threatening arrhythmic event was defined as an episode of spontaneous ventricular tachycardia Ͼ30 s, resuscitated cardiac arrest, or appropriate implantable cardioverterdefibrillator discharge (antitachycardia pacing or defibrillation). HF progression was defined as an increase in NYHA functional class from II to III or IV or from III to IV. The primary results of the ADMIRE-HF trial were previously presented and published (12) . Echocardiographic analysis. For trial inclusion, a site-reported LVEF could be based on assessment by echocardiography, radionuclide ventriculography, electrocardiography-gated single-photon emission computed tomography myocardial perfusion imaging, contrast ventriculography, or cardiac magnetic resonance. For quality assurance purposes, sites also submitted echocardiograms to an independent core laboratory for quantitative assessment 
Shah et al. 123 I-mIBG, LVEF, and Outcomes in HF of LV volumes and LVEFs. All echocardiograms were evaluated in a core laboratory blinded to both H/M ratio and clinical status. Ventricular volumes were determined by the Simpson method in the apical 4-chamber view, and LVEF was calculated from volumes in the standard manner (14) .
Of 901 patients with a core laboratorydetermined LVEF, 813 (90%) had site LVEF measured by echocardiography. Of these 813 patients, the same echocardiogram was used for site assessment and core laboratory analysis in 707 (87%). In the remaining 106 patients (13%), the study used for site LVEF assessment and core laboratory analysis were separated by a mean of 32 days (range, 1 to 439 days). In 88 patients (10%), the site-reported LVEF was based on a modality other than echocardiography, and in 59 (67%) of these patients, the study used for site assessment of LVEF was performed on a different day from the echocardiogram analyzed by the core laboratory (mean difference, 26 days; range, 1 to 50 days). Statistical methods. We dichotomized subjects based on core laboratory-adjudicated LVEFs Յ35% or Ͼ35% to describe baseline clinical and imaging parameters. Continuous variables are presented as mean and SD unless otherwise specified, and between-group comparisons were performed using a Fisher exact test for categorical variables and a t test for continuous variables. Two-sided p values Ͻ0.05 were considered significant. Sample size was allowed to float.
We assessed for effect modification using 2 methods. First, multivariable Cox proportional hazard models were used to evaluate for effect modification of LVEF on the relationship between H/M ratio and the following outcomes: arrhythmic event or death and a composite of cardiac death, HF progression, and arrhythmic event. All models adjusted for age, sex, baseline NYHA functional class, HF etiology (ischemic or nonischemic), diabetes status, history of hypertension, and baseline B-type natriuretic peptide level. A p value Ͻ0.05 was considered significant. Second, to better define the magnitude of risk associated with low H/M ratio across the continuum of observed LVEFs, we used local regression plots of the adjusted hazard ratio associated with an H/M ratio Ͻ1.6 by LVEF as a continuous measure using multivariable local regression (15) . The hazard ratio associated with a low H/M ratio was plotted for every second percentile of LVEF incorporating patients with baseline LVEF within the 15 percentiles above and below that point such that 30% of the study population contributed to each effect estimate.
To assess the incremental value of the H/M ratio beyond clinical characteristics, biomarker data, and LVEF, analysis was restricted to 542 subjects (355 with core laboratory LVEFs Յ35% and 187 with LVEFs Ͼ35%) with at least 475 days of follow-up. Multivariable logistic regression models for the cardiovascular composite outcome and for death or arrhythmic event were built, either including or excluding H/M ratio data. All models adjusted for age, sex, baseline NYHA functional class, HF etiology (ischemic or nonischemic), diabetes status, history of hypertension, baseline B-type natriuretic peptide level, and core laboratory-adjudicated LVEF. The area under the receiver-operating characteristic curve was expressed as the C-statistic and tested whether p event Ͼ p nonevent , where p event is the model predicted probability of an event from the logistic regression model among individuals who experienced an event and p nonevent is the model predicted probability of an event among individuals who did not experience an event. The model C-statistic was compared among models with versus without H/M ratio. C-statistics were compared using the Delong test (16) . The integrated discrimination improvement (IDI) was calculated as IDI ϭ (p with H/M, event Ϫ p without H/M, event ) Ϫ (p with H/M, nonevent Ϫ p without H/M, nonevent ), where p with H/M, event is the predicted probability of an event from the logistic regression model containing the H/M ratio data among individuals who experienced an event, p without H/M, event is the predicted probability of an event from the logistic regression model not containing the H/M ratio data among individuals who experienced an event, p with H/M, nonevent is the predicted probability of an event from the logistic regression model containing H/M ratio data among individuals who did not experience an event, and p without H/M, nonevent is the predicted probability of an event from the logistic regression model not containing H/M ratio data among individuals who did not experience an event (17) .
R E S U L T S
Baseline characteristics. Of 985 subjects enrolled in the ADMIRE-HF trial, 123 I-mIBG imaging results, core laboratory-determined LVEFs, and complete follow-up were available for 901 subjects (91.5% of enrolled subjects) who were included in this analysis. The mean site-reported LVEF was 27.1 Ϯ 6.2 ( Fig. 1) . One subject with a reported LVEF Ͼ35% at 2 days before 123 I-mIBG imaging was allowed to remain in the study based on an earlier determination of 35%. The mean core laboratory-adjudicated LVEF was 34.2 Ϯ 6.9 and 386 (43%) had an LVEF Ͼ35%. Using a Bland-Altman analysis of agreement between site-reported LVEF and core laboratory-measured LVEF, the bias estimate for site-core laboratory LVEF was Ϫ7.1% with 95% limits of agreement of Ϫ21.9% to 7.7%.
The mean LVEF of the 515 subjects with an LVEF Յ35% was 29.5 Ϯ 3.7%, and the mean LVEF of the 386 subjects with an LVEF Ͼ35% was 40.4 Ϯ 5.0%. Subjects with an LVEF Ͼ35% were more frequently female, more frequently had HF of ischemic etiology, had lower body mass index, and had lower baseline B-type natriuretic peptide levels (Table 1) . A modest, although statistically significant, correlation was noted between LVEF and H/M ratio as a continuous measure (Pearson correlation coefficient ϭ 0.23, p Ͻ 0.0001). LVEF, H/M ratio, and clinical events. Cumulative incidence, event rates, and adjusted hazard ratio for clinical events by LVEF category and H/M ratio are shown in Table 2 . Subjects with an LVEF Յ35% were at higher risk of both the composite of cardiac death, arrhythmic event, and worsening HF and of death or arrhythmic event compared with subjects with an LVEF Ͼ35%. An H/M ratio Ͻ1.6 was associated with an increased relative risk of both endpoints without evidence of significant effect modification by LVEF category (Յ35% or Ͼ35%). Figure 2 illustrates the rate of death or arrhythmic event by H/M ratio among 4 categories of core laboratory LVEF, demonstrating consistent trends toward higher event rates with an H/M ratio Ͻ1.6 in all categories. As demonstrated in Figure 3 , no significant heterogeneity of the relative risk associated with an H/M ratio Ͻ1.6 was detected across the continuum of LVEF for either of the clinical endpoints.
Incremental value of H/M ratio beyond clinical characteristics and LVEF in predicting clinical outcomes in
patients with HF and LVEF <35% and >35%. For the cardiovascular composite endpoint, information on H/M ratio did not significantly affect the model C-statistic (Table 3) . A small but significant improvement in the IDI was noted, the magnitude of which was most prominent in the LVEF Ͼ35% group. For the outcome of death or arrhythmic event, the addition of H/M ratio led to significant improvement in both the C-statistic and the IDI. For both measures, the magnitude of effect 
Figure 1. LVEF Distribution in the ADMIRE-HF Trial
Distribution of the site-reported (pink columns) and echocardiography core laboratoryadjudicated left ventricular ejection fraction (LVEF) (green columns). The mean site-reported LVEF was 27.1 Ϯ 6.2. The mean core laboratory-adjudicated LVEF was 34.2 Ϯ 6.9, and 386 (43%) subjects had an LVEF of Ͼ35%. appeared greater among subjects with an LVEF Ͼ35%.
D I S C U S S I O N
Of 901 subjects enrolled in the ADMIRE-HF trial with H/M ratio data and core laboratory LVEFs, 384 (43%) had an LVEF Ͼ35%. We found no evidence of effect modification of LVEF on the relationship between H/M ratio and risk, either of death or arrhythmic event or of the composite endpoint of cardiac death, arrhythmic event, and worsening HF. For the outcome of death or arrhythmic event, information on H/M ratio appeared to improve discrimination of predictive models beyond clinical, biomarker, and LVEF data, particularly among subjects with an LVEF Ͼ35%. Multiple single-center studies have demonstrated an association between abnormal cardiac sympathetic innervation imaging, reflected in a low H/M ratio, and worse outcomes among patients with HF (10). However, the majority of studies evaluated patients with HF and low LVEF, and only limited data exist regarding the performance of this test in HF patients with normal or only slightly reduced LVEF (18 -20) . In a multicenter study of 290 patients, Agostini et al. (18) demonstrated a relationship between H/M ratio and cardiovascular events among the 191 subjects with an LVEF Յ35% but not among the 99 patients with an LVEF Ͼ35%. Studies have demonstrated that the washout rate, but not the H/M ratio, was predictive of events among patients with an LVEF Ͼ35% to 40% (19, 21) . Among HF patients with a broad range of core laboratory-adjudicated LVEFs, including 386 subjects with an LVEF Ͼ35%, we did not detect evidence of heterogeneity by LVEF in the association between low H/M ratio and risk of cardiovascular events.
Although the risk of sudden death is especially pronounced among HF patients with significant LV dysfunction, it is also the most common cause of cardiovascular death among patients with HF and normal or slightly reduced systolic function, accounting for 26% to 28% of total mortality (1,2). However, the ability to effectively risk-stratify these patients is limited. Although LVEF is a powerful predictor of mortality and sudden death when significantly reduced, it is less useful in riskstratifying those patients with normal or only slightly reduced LVEF (Ͼ45%) (3). Given the role 
Figure 2. Event Rates by LVEF and H/M Ratio
Rates of death or arrhythmic event by 4 categories of core laboratory-adjudicated left ventricular ejection fraction (LVEF) and heart-to-mediastinum ratio (H/M ratio). Values above each column represent the event rate per 100 person-years, number of events, and percentage of patients experiencing an event. Hazard ratios (HRs) were determined using multivariable Cox proportional hazards models adjusting for baseline New York Heart Association (NYHA) functional class and log of baseline B-type natriuretic peptide (BNP) level. (12) 2 (2) 21 (5) 20 (7) 1 (1) CV death 33 (6) 32 (7) 1 (1) 13 (3) 12 (4) 1 (1) Arrhythmic event 48 (9) 44 (10) 4 (5) 14 (4) 13 (5) 1 (1) Worsening HF 117 (23) 106 (24) 11 (13) 48 (12) 40 (14) 8 (7) Arrhythmic event or death 95 (18) 89 (21) Values are n (%) or n (range). *Adjusted for age, sex, heart failure etiology, NYHA functional class, diabetes status, hypertension, and B-type natriuretic peptide level. CV ϭ cardiovascular; HF ϭ heart failure; H/M ratio ϭ heart-to-mediastinum ratio; HR ϭ hazard ratio; LVEF ϭ left ventricular ejection fraction; other abbreviation as in Table 1 .
of cardiac autonomic innervation in the pathogenesis of ventricular arrhythmias (22) , sympathetic innervation imaging has the potential to identify subjects at increased risk of life-threatening arrhythmia, although data regarding the relationship between H/M ratio and spontaneous arrhythmias in patients with implantable cardioverter-defibrillators (23) or inducible arrhythmias on electrophysiological testing (24) has been inconsistent. Our findings suggest that a low H/M ratio is associated with a higher risk of death or arrhythmic event across the spectrum of LVEFs, including HF patients with an LVEF Ͼ35%. Also, although limited by power, our exploratory analysis of the impact of H/M ratio data on model performance (C-statistic) and reclassification indexes (IDI) suggests that for the outcome of death or arrhythmic event, information on the H/M ratio improves risk discrimination beyond clinical, biomarker, and LVEF data. These findings suggest that 123 I-mIBG imaging may hold promise to improve risk stratification among HF patients with an LVEF Ͼ35% if future adequately powered prospective studies can confirm these hypothesisgenerating findings. Study limitations. All patients had a site-reported LVEF of Յ35%. Although we noted a quantitative core laboratory LVEF Ͼ35% in 386 patients (43% of the trial population), the core laboratory LVEF was still Ͻ40% in the majority of these (n ϭ 229, 59%) and was Ͻ45% in a large majority (n ϭ 324, 84%). These differences may partly relate to a difference in timing and/or modality of study used by site and core laboratory in nearly one-fourth of subjects because the confidence limits for serial assessments of the LVEF in an individual at 2 time points are approximately 10% (25) . Differences in the remainder of cases may partly relate to interreader variability, which approximates 7%, even when both assessments are measured quantitatively (5, 25) . Finally, in multicenter clinical trials using LVEF cutoffs for inclusion, discordance between enrolling site and core laboratory assessment is not unusual (7) . Although this analysis provides information on the performance of sympathetic innervation imaging in HF patients with lesser degrees of impairment in LV systolic function, it does not represent the HF with preserved ejection fraction population. The timing between performance of the echocardiogram read by the core laboratory and the 123 I-mIBG imaging varied. The relationship between appropriate implantable cardioverterdefibrillator therapy and sudden death is unclear. HF progression determined by increased NYHA functional class is subjective, although this endpoint was centrally adjudicated. The analyses were underpowered to detect an interaction by LVEF on the relationship between the H/M ratio and clinical events. They were similarly underpowered to detect incremental benefit of the H/M ratio beyond LVEF, biomarkers, and clinical data, especially when stratified by LVEF. For the LVEF Ͼ35% subgroup, adjusted effect estimates for death or ar- rhythmic event may be overfitted, although results were qualitatively similar as observed in unadjusted analyses. However, this population is the largest to our knowledge with data on the H/M ratio and clinical outcomes in HF patients with an LVEF Ͼ35%.
C O N C L U S I O N S
Myocardial sympathetic innervation imaging with 123 I-mIBG has prognostic value across a broad spectrum of LVEFs for death or arrhythmic event and for cardiovascular death, arrhythmic event, and HF progression. For the outcome of death or arrhythmic event in particular, 123 I-mIBG imaging appears to improve risk discrimination beyond clinical and biomarker data regardless of the LVEF. These findings suggest that further prospective studies may be warranted to evaluate the prognostic value of 123 I-mIBG imaging in patients with HF and an LVEF Ͼ35%. Table 2 . Shah et al. 123 I-mIBG, LVEF, and Outcomes in HF
